(2S,3S)-N-(5-t-butyl-2-methoxyphenyl)methyl-2-diphenylmethyl-1-azabicyclo[2.2.2.]octan-3-amine | 863879-46-3

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: (2S,3S)-N-(5-t-butyl-2-methoxyphenyl)methyl-2-diphenylmethyl-1-azabicyclo[2.2.2.]octan-3-amine
• 英文别名: (2S,3S)-N-(5-tert-butyl-2-methoxyphenyl)methyl-2-diphenylmethyl-l-azabicyclo[2.2.2]octan-3-amine；(2S,3S)-N-(5-tert-butyl-2-methoxyphenyl)-methyl-2-diphenylmethyl-1-azabicyclo[2.2.2]-octan-3-amine；(2S,3S)-N-(5-tert-butyl-2-methoxyphenyl)methyl-2-diphenylmethyl-1-azabicyclo[2.2.2]-octane-3-amine；N-[(5-tert-Butyl-2-methoxyphenyl)methyl]-2-(diphenylmethyl)-1-azabicyclo[2.2.2]octan-3-amine；2-benzhydryl-N-[(5-tert-butyl-2-methoxyphenyl)methyl]-1-azabicyclo[2.2.2]octan-3-amine
• CAS: 863879-46-3
• 化学式: C₃₂H₄₀N₂O
• 分子量: 468.682
• InChiKey: OMPCVMLFFSQFIX-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  7
• 重原子数：
  35
• 可旋转键数：
  8
• 环数：
  6.0
• sp3杂化的碳原子比例：
  0.44
• 拓扑面积：
  24.5
• 氢给体数：
  1
• 氢受体数：
  3

文献信息

• [EN] PROCESS FOR PREPARATION OF 1-(2S,3S)-2-BENZHYDR YL-N-(5-TERT-BUTYL-2-METHOXYBENZYL)QUINUCLIDIN-3-AMINE<br/>[FR] PROCEDE DE PREPARATION DE 1-(2S,3S)-2-BENZHYDRYL-N-(5-TERT-BUTYL-2-METHOXYBENZYL)QUINUCLIDINE-3-AMINE
  申请人：PFIZER PROD INC

  公开号：WO2005075473A1

  公开（公告）日：2005-08-18

  This invention relates to an improved process for the preparation of (2S,3S)-­ 2-benzhydryl-N-(5-tent-butyl-2-methoxybenzyl)quinuclidin-3-amine, (hereinafter 'compound of Formula I') and its pharmaceutically acceptable salts. In particular, the invention is directed to an improved synthesis of the monohydrate citrate salt of the compound of Formula (la).

  本发明涉及一种改进的工艺，用于制备(2S,3S)-2-苯甲基-N-(5-叔丁基-2-甲氧基苯基)喹诺啉-3-胺（以下简称“公式I化合物”）及其药学上可接受的盐。特别地，本发明针对公式(la)化合物的单水合柠檬酸盐的合成进行了改进。
• Process for preparation of 1-(2s,3s)-2-benzhydryl-n-(5- tert-butyl-2-methoxybenzyl)quinuclidin-3-amine
  申请人：Basford Patricia A.

  公开号：US20090099364A1

  公开（公告）日：2009-04-16

  This invention relates to an improved process for the preparation of (2S,3S)-2-benzhydryl-N-(5-tent-butyl-2-methoxybenzyl)quinuclidin-3-amine, (hereinafter “compound of Formula I”) and its pharmaceutically acceptable salts. In particular, the invention is directed to an improved synthesis of the monohydrate citrate salt of the compound of Formula (Ia).

  本发明涉及一种改进的制备(2S,3S)-2-苯甲基-N-(5-叔丁基-2-甲氧基苯基)喹诺啉-3-胺(以下简称"公式I化合物")及其药学上可接受的盐的方法。特别地，本发明涉及一种改进的合成公式(Ia)化合物的单水合柠檬酸盐的方法。
• Process for the synthesis of 2-benzhydryl-3 quinuclidinone
  申请人：Procos S.P.A.

  公开号：US11286254B2

  公开（公告）日：2022-03-29

  The present invention discloses a process for the preparation of 2-benzhydryl-3-quinuclidinone (1). (I). The process of the invention allows to obtain the intermediate 2-benzhydryl-3-quinuclidinone (1) by reaction of 2-benzylidene-3-quinuclidinone (2) with the Grignard reagent phenyl-magnesium halide, in particular chloride or bromide, in the presence of catalytic amounts of copper (I) salts. Taking advantage of the high efficiency of the catalytic system of the copper (I) salts, 2-benzhydryl-3-quinuclidinone (1) is obtained in higher yields than those of the known processes. Advantageously, since the amounts of copper (I) salts are catalytic, the latter can easily be removed from the reaction mixture, and the process is carried out in the presence of solvents less toxic and expensive than those used in the state of the art.

  本发明公开了一种制备2-双苯甲基-3-喹诺里西啶酮(1)的方法。(I)。本发明的方法允许通过将2-苯甲酰基-3-喹诺里西啶酮(2)与格氏试剂苯基镁卤化物反应，特别是在铜(I)盐催化量的存在下，获得中间体2-双苯甲基-3-喹诺里西啶酮(1)。利用铜(I)盐催化系统的高效性，可获得比已知方法更高的产率的2-双苯甲基-3-喹诺里西啶酮(1)。而且，由于铜(I)盐的使用量是催化量，它们可以很容易地从反应混合物中去除，并且该过程在毒性较低、成本较低的溶剂存在下进行，与现有技术中使用的溶剂相比。
• Use of tachykinin antagonists, including NK-1 receptor antagonists, to modify unwanted behavior in dogs, cats and horses
  申请人：——

  公开号：US20030139443A1

  公开（公告）日：2003-07-24

  The present invention relates to a method of treating abnormal anxiety behavior in companion animals comprising administering to a companion animal in need thereof a therapeutically effective amount of an NK-1 receptor antagonist.

  本发明涉及一种治疗伴侣动物异常焦虑行为的方法，包括向有需要的伴侣动物施用治疗有效量的 NK-1 受体拮抗剂。
• USE OF NK-1 RECEPTOR ANTAGONISTS TO MODIFY UNWANTED BEHAVIOR IN DOGS, CATS AND HORSES
  申请人：Pfizer Products Inc.

  公开号：EP1411946A1

  公开（公告）日：2004-04-28